BIOMARCK PHARMACEUTICALS

BioMarck Pharmaceuticals, Ltd. is a privately owned biopharmaceutical company dedicated to the discovery and development of new drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are la... ter disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and a Phase 2 study of the efficacy of BIO-11006 in COPD patients. Data from the Phase 2 study demonstrated proof-of-concept of BIO-11006. BioMarck licensed its technology on a worldwide exclusive basis from North Carolina State University, based on the work of Kenneth B. Adler, Ph.D., Professor of Cell Biology, and his co-workers.More